Pfizer Cuts 150 Jobs, Along With Broader R&D Reconfigurations
Pfizer is ending five preclinical programs in the biosimilar area and cutting 150 positions in Lake Forest, Illinois and in Chennai, India.
7 Biotech Trends to Look Out for in 2019
Here are seven trends most likely to be hitting the news cycle in 2019 according to BioSpace.
CDC: 14 Million Americans Will Have Alzheimer’s by 2060
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Potential blood test for Alzheimer’s shows promise
Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease.
Pfizer Confirms Neuroscience Cuts, Shelves Another Four Early-Stage Projects
Pfizer released an update of the company’s pipeline, including eight different discontinued projects in the field of neuroscience.
Eisai and Boston University School of Medicine Announce Research Collaboration to Study the Effects of Alzheimer’s Disease-associated Genetic Variants on Brain
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
Bill Gates makes $100 million personal investment to fight Alzheimer’s
Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.
Despite $9B Setback, Eli Lilly Boldly Moves on With Five New Alzheimer’s Candidates
During a fireside chat at BIO International in San Diego in summer 2017, Daniel Skovronsky – now president of Lilly Research Labs – confirmed Eli Lilly’s commitment to finding an effective therapy for Alzheimer’s disease. Lilly continues to push forward. EP Vantage highlighted and analyzed the company’s five Phase I programs for Alzheimer’s disease. Much like what Skovronsky said about learning from the Phase III solanezumab failure, EP Vantage pointed to some of the hopes the Lilly programs have for blocking the development of amyloid plaques.
Lilly Seeking “Voluntary Exits” From Researchers
After terminating 485 positions linked to its failed Alzheimer’s therapy solanezumab, Lilly aims to terminate another 3 percent of R&D staff, Endpoints reported.
Eli Lilly Ends Another Solanezumab Phase 3 Study
Lilly has closed off another avenue for solanezumab, its once-promising experimental therapy for Alzheimer’s disease, after scrapping another Phase III study.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!